Review
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1406-1428
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1406
Table 1 Subcategories of poorly cohesive cell carcinoma as proposed by the Verona consensus[16] in two recent clinical studies[47,48]
Ref.Category of PCC
SRC type: > 90% of Signet Ring cells
PCC with SRC component: < 90% but > 10% of SRC
PCC-NOS: < 10% of SRC
Bencivenga et al[47]32 (18.5)98 (56.6)43 (24.9)
Roviello et al[48]0 (0)87 (60.8)56 (39.2)
Table 2 Concordance rates between World Health Organization and Laurén classification systems
Ref.
Reclassification of SRC and PCC-GC according to Laurén classification
n
% Intestinal
% Diffuse
% Mixed
Pyo et al[7], 201631700.696.33.1
Pyo et al[173], 201753090.096.13.9
Wanebo et al[174],199318728711
Hass et al[175], 20111607.666.226.2
Lee et al[176], 2012 3200.090.69.4
Heger et al[58], 20142350.075.320.0
Chon et al[53], 201716461.296.42.4
Table 3 Summary of studies reporting the all-stage prognostic value of signet ring cell- and poorly cohesive cell-gastric cancer
Ref.
n
n SRC-CG (%)
% LNM
5-yr survival rate %, SR-CGC vs other
Univariate
Multivariate
Compared to
Eastern studies
Maehara et al[49], 1992150051 (3.4)33.374.5 vs 52.4P < 0.01-Non SRC-GC
Kim et al[177], 19943702450 (12.2)50.659.7 vs 57.7/48.6/43.1NS-WD/MD/PD
Otsuji et al[178], 19981498154 (10.3)27.968.2 vs 43.9 (10-yr survival rate)P < 0.05-Non SRC-GC
Yokota et al[179], 199892393 (10.1)43WorseNS-Non SRC-GC
Kim et al[180], 20042358204 (8.7)26.560.2 vs 48.9P < 0.01NSNon SRC-GC
Park et al[181], 20082275251 (11.0)46.266.2 vs 66.7/54.5/51.0WD: NS; PD/MC: P < 0.001P = 0.002aWD/PD/MC
Zhang et al[45], 2010 1439218 (15.1)76.144.9 vs 36P = 0.013NSNon SRC-GC
Chiu et al[182], 20112439505 (20.7)53.757.6 vs 56NS-Non SRC-GC
Jiang et al[55], 20111439211 (14.7)52,049.8 vs 41.4P = 0.001-Non SRC-GC
Lee et al[176], 20121002320 (31.9)37.284.8 vs 71.9/57.8P < 0.001NSPD/MC
Kwon et al[50], 2014769108 (14.0)43.555.4 vs 64.5/46.2 (10-yr survival rate)P < 0.001NSWD-MD/PD-MC
Liu et al[162], 2015 1464138 (9.4)30.436.2 vs 49.5P < 0.001P < 0.001Non SRC-GC
Chon et al[53], 201776671646 (21.5)25.880.0 vs 70.0 (10-y survival rate)P < 0.001NSWMD/PD
Lu et al[183], 2016 2199354 (16.1)-15.9 mo vs 22.1 moP = 0.002< 0.001Non SRC-GC
Western studies
Theuer et al[184], 19993020453 (15.0)NRSimilarNSNSNon SRC-GC
Piessen et al[35], 200918059 (32.8)83.128 vs 46P = 0.004P = 0.004Non SRC-GC
Taghavi et al[44], 2012102462666 (26)59.7Similar (Disease-specific survival)NSP = 0.15Non SRC-GC
Bamboat et al[51], 2014569210 (36.9)61.049 vs 24/43 (5-y cumulative-mortality)P < 0.0001-WMD/PD
Postlewait et al[6], 2015 768312 (40.6)66.333.7 mo vs 46.6 mo (OS)P = 0.011NSNon SRC-GC
Voron et al[8], 20161799899 (50)73.226 mo vs 51 mo (median survival)P < 0.001P < 0.041Non SRC-GC
Table 4 Summary of studies reporting prognostic value of signet ring cell- and poorly cohesive cell-early gastric cancer
Ref.
n
n SRC-GC (%)
% LNM
5-yr survival rate %, SRC-GC vs other
Univariate
Multivariate
Compared to
Eastern studies
Maehara et al[49], 199238428 (7.3)10.7100 vs 94.8NS-Non SRC-GC
Kim et al[177], 1994785185 (23.6)7.692.9 vs 83.9/87.3/93.6NS-WD/MD/PD
Otsuji et al[178], 199856894 (16.5)5.393 vs 76.3P < 0.05-Non SRC-GC
Yokota et al[179], 199825341 (16.2)-SimilarNS-Non SRC-GC
Hyung et al[80], 2002933263 (28.2)5.794.2 vs 91.6P = 0.01-Non SRC-GC
Kim et al[180], 200456194 (16.8)2.196.3 vs 90.8NSNSNon SRC-GC
Kunisaki et al[185], 2004513120 (23.4)9.2BetterP = 0.033P = 0.036Non SRC-GC
Ha et al[186], 20081520388 (25.5)9.599.7 vs 99.1/97.2NS/P = 0.019-WMD-PA/PD-MC
Zhang et al[45], 201013849 (35.5)-SimilarNS-Non SRC-GC
Chiu et al[182], 2011579149 (25.7)10.796.1 vs 89.6P = 0.01-Non SRC-GC
Jiang et al[55], 201126954 (20.1)16.794.3 vs 90.6P = 0.007P = 0.011Non SRC-GC
Kwon et al[50], 201432651 (15.6)9.884.0 vs 76.0/65.7 (10-yr survival rate)NS-WD-MD/PD-MC
Kim et al[52], 20142085345 (16.5)9.0%Similar (disease-related survival)NS-WD/MD/PD
Wang et al[187], 2015334115 (34.4)8.593.9 vs 85.8P = 0.0270.001UD
Chon et al[53], 201732721091 (33.3)-95 vs 85 (10-yr survival rate)P < 0.001P = 0.041 (WMD)WMD-PD
Imamura et al[188], 2016746152 (20.4)2.097.4 vs 89.9P = 0.012P = 0.038Non SRC-GC
Western studies
Gronnier et al[54], 2013421104 (24.7)24,085 vs 76P = 0.035NSNon SRC-GC
Bamboat et al[51], 2014437174 (39.8)-0 vs 8/24 (5-disease-specific mortality)P = 0.001-WMD/PD
Table 5 Summary of studies reporting prognostic value of signet ring cell- and poorly cohesive cell-gastric cancer
Studies
n
n SRC (%)
% LNM
5-yr survival rate % (PCC-GC vs other)
Univariate
Multivariate
Compared to
Eastern studies
Maehara et al[49], 1992 111623 (2.1)60.842.5 vs 37.6NS-Non SRC-GC
Kim et al[177], 1994 2917265 (9.1)80.833 vs 45.4/38.8/35.3P < 0.05-WD/MD/PD
Otsuji et al[178], 199893060 (6.4)63.344.4 vs 27.5 (10-yr survival rate)NS-Non SRC-GC
Yokota et al[179], 199843052 (12.1)-WorseNS-Non SRC-GC
Kunisaki et al[185], 200460054 (9.0)57.4SimilarNS-Non SRC-GC
Kim et al[180], 20041797110 (6.1)47.335.1 vs 39.5NS-Non SRC-GC
Li et al[56], 20074759662 (13.9)75.742.4 vs 50.10.009NSNon SRC-GC
Chiu et al[182], 20111860356 (19.1)71.641.5 vs 46.3P = 0.018-Non SRC-GC
Jiang et al[55], 20112046157 (7.7)64.331.5 vs 35.7NSNSNon SRC-GC
Zu et al[57], 201474144 (5.9)56.843.4 vs 87.1/57.1/50.6/62.7P = 0.0120.028WD/MD/PD/MC
Kwon et al[50], 201444357 (12.9)73.726.0 vs 50.5/38.4 (10-yr survival rate)P = 0.044NSWD-MD/PD-MC
Chon et al[53], 20171777555 (31.2)-53 vs 58/52 (10-yr survival rate)P < 0.001P < 0.001WMD/PD
Western studies
Heger et al[58], 2014723235 (32.5)63.026.3 vs 46.6 mo (median survival)P < 0.001P = 0.02 (backward analysis)Non SRC-GC